Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score

por Tapper, Elliot B., Hunink, M. G. Myriam, Afdhal, Nezam H., Lai, Michelle, Sengupta, Neil
Publicado 2016

Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD

por Vieira Barbosa, Joana, Milligan, Scott, Frick, Andrew, Broestl, Jeremy, Younossi, Zobair, Afdhal, Nezam H., Lai, Michelle
Publicado 2021

Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational s...

por Curry, Michael P, Flamm, Steven L, Milligan, Scott, Tsai, Naoky, Wick, Nicole, Younossi, Zobair, Afdhal, Nezam H
Publicado 2021

A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease

por Danford, Christopher J., Connelly, Margery A., Shalaurova, Irina, Kim, Misung, Herman, Mark A., Nasser, Imad, Otvos, James D., Afdhal, Nezam H., Jiang, Z. Gordon, Lai, Michelle
Publicado 2018

Differential Associations of Circulating MicroRNAs With Pathogenic Factors in NAFLD

por Ezaz, Ghideon, Trivedi, Hirsh D., Connelly, Margery A., Filozof, Claudia, Howard, Kellie, L.Parrish, Mark, Kim, Misung, Herman, Mark A., Nasser, Imad, Afdhal, Nezam H., Jiang, Z. Gordon, Lai, Michelle
Publicado 2020

First‐line therapies for hepatitis B in the United States: A 3‐year prospective and multicenter real‐world study after approval of tenofovir alefenamide

por Pan, Calvin Q., Afdhal, Nezam H., Ankoma‐Sey, Victor, Bae, Ho, Curry, Michael P., Dieterich, Douglas, Frazier, Lynn, Frick, Andrew, Hann, Hie‐Won, Kim, W. Ray, Kwo, Paul, Milligan, Scott, Tong, Myron J., Reddy, K. Rajender
Publicado 2022

Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years

por Buti, Maria, Fung, Scott, Gane, Edward, Afdhal, Nezam H., Flisiak, Robert, Gurel, Selim, Flaherty, John F., Martins, Eduardo B., Yee, Leland J., Dinh, Phillip, Bornstein, Jeffrey D., Mani Subramanian, G., Janssen, Harry L. A., George, Jacob, Marcellin, Patrick
Publicado 2015

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

por Loomba, Rohit, Lawitz, Eric, Mantry, Parvez S., Jayakumar, Saumya, Caldwell, Stephen H., Arnold, Hays, Diehl, Anna Mae, Djedjos, C. Stephen, Han, Ling, Myers, Robert P., Subramanian, G. Mani, McHutchison, John G., Goodman, Zachary D., Afdhal, Nezam H., Charlton, Michael R.
Publicado 2017

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis

por Sanyal, Arun J., Anstee, Quentin M., Trauner, Michael, Lawitz, Eric J., Abdelmalek, Manal F., Ding, Dora, Han, Ling, Jia, Catherine, Huss, Ryan S., Chung, Chuhan, Wong, Vincent Wai‐Sun, Okanoue, Takeshi, Romero‐Gomez, Manuel, Muir, Andrew J., Afdhal, Nezam H., Bosch, Jaime, Goodman, Zachary, Harrison, Stephen A., Younossi, Zobair M., Myers, Robert P.
Publicado 2022